🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Biotech startup Pandorum Technologies raises $18 Mn in Series B round

EntrackrEntrackr · 7h ago
Biotech startup Pandorum Technologies raises $18 Mn in Series B round
Medial

Biotech startup Pandorum Technologies raises $18 Mn in Series B round Biotech startup Pandorum Technologies has raised $18 million in a Series B funding round led by Protons Corporate, with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others. Entrackr had exclusively reported the current development in November last year. The funding round was completed in two tranches, with the first tranche in November and the second in December. According to Entrackr’s analysis, the company will be valued at around Rs 822 crore (around $91 million) post money. The proceeds will be used to advance clinical programs, scale manufacturing, and expand market access across the U.S., Japan, and the Middle East. A portion of the funds will also be deployed towards strengthening regulatory and clinical capabilities. Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates in the regenerative medicine and biotechnology space, focusing on programmable, exosome-based tissue regenerative therapies. The company has operations in India and the United States. The brand follows a globally distributed manufacturing strategy. It has partnered with AGC Biologics for manufacturing support in the U.S. and Europe, and Nucelion Therapeutics, a subsidiary of Bharat Biotech, for supply across the Asia-Pacific region. The company is also exploring partnerships in the Middle East. According to TheKredible, the company has raised around $43 million to date, including the $11 million secured last year as an extension of its Series A. Pandorum has yet to file its FY25 financials. In FY24, the company was in a pre-revenue stage and reported losses of Rs 28.2 crore. Disclaimer: Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever.

Related News

Exclusive: Biotech firm Pandorum to raise $10 Mn in Series B

EntrackrEntrackr · 2m ago
Exclusive: Biotech firm Pandorum to raise $10 Mn in Series B
Medial

Pandorum Technologies, a Bengaluru-based biotechnology startup focused on tissue engineering, is raising Rs 85 crore (around $10 million) in its Series B round led by Protons Corporate, along with participation from a clutch of other investors. The company’s board has approved a special resolution to issue 35,326 Series B preference shares at an issue price of Rs 23,920 each, according to regulatory filings sourced from the Registrar of Companies. Protons Corporate, managed by Anand Karbhari, is leading the round with Rs 27 crore, while Noblevast Advisory is contributing Rs 16.1 crore. A set of well-known angel investors, including Ashish Kacholia, Ankit Kawatra, Kishore Jagjival Gokal, Srinivas Rao Ravuri, and Kailash Ramlal Jhaveri, are also participating in the fundraising. As per the filings, Pandorum has already received Rs 45 crore from this round, with the remaining capital expected to be infused soon. The fresh funds will be deployed towards the company’s operational requirements, expansion plans, and to provide financial support to its wholly-owned subsidiaries. Entrackr’s estimates peg Pandorum’s post-money valuation at around Rs 750 crore ($85 million) following this transaction. Before this round, the company had secured $11 million last year as an extension of its Series A. Earlier, it had raised Rs 41 crore in 2020 and Rs 23 crore in 2017. Founded in 2011 by Arun Chandru and Tuhin Bhowmick, Pandorum Technologies builds lab-grown human tissues for drug discovery and regenerative medicine. Its engineered liver and corneal models, developed on a proprietary bioprinting platform, are used by pharma companies for high-precision testing and research. The company monetises through contract research, licensing, and long-term co-development partnerships, positioning it among the few IP-heavy deep-science ventures in India. Pandorum is yet to file its FY25 numbers. In FY24, Pandorum remained in the pre-revenue stage while posting losses of Rs 28.2 crore.

Exclusive: Gauri Khan Family Trust to back Pandorum in ongoing Series B

EntrackrEntrackr · 1m ago
Exclusive: Gauri Khan Family Trust to back Pandorum in ongoing Series B
Medial

Exclusive: Gauri Khan Family Trust to back Pandorum in ongoing Series B Pandorum Technologies, a Bengaluru-based biotechnology startup, is raising an additional Rs 71.5 crore ($8 million) in its ongoing Series B round, led by Trufort Fund Limited, with participation from Gauri Khan Family Trust and others. Pandorum Technologies is raising additional funds in its Series B round, led by Trufort Fund Limited, and including contributions from Gauri Khan Family Trust and existing investors like Protons Corporate and Noblevast Advisory. Previously, they raised a $10 million tranche led by Protons Corporate. The board has issued 29,893 Series B cumulative compulsory convertible preference shares at Rs 23,920 each, according to the Registrar of Companies (RoC). Trufort Fund Ltd will invest Rs 20 crore, Protons Corporate and Saumik Doshi Rs 10 crore each, Noblevast Advisory Rs 9.5 crore, and Gauri Khan Family Trust Rs 5 crore. Avinya Ventures and others will cover the remaining Rs 27 crore. The fresh capital will support operational needs, expansion initiatives, and subsidiaries. The company’s valuation is expected to be around Rs 822 crore ($91 million) post-money. Founded in 2011 by Arun Chandru and Tuhin Bhowmick, Pandorum Technologies develops lab-grown human tissues for drug discovery and regenerative medicine, offering engineered liver and corneal models for pharmaceutical testing. To date, the company has raised around $43 million, including $11 million as an extension of its Series A. Pandorum is yet to file FY25 numbers. In FY24, the company remained pre-revenue with losses of Rs 28.2 crore.

Healthcare edtech startup Virohan raises $7.5 Mn in ongoing Series B

EntrackrEntrackr · 1m ago
Healthcare edtech startup Virohan raises $7.5 Mn in ongoing Series B
Medial

Healthcare edtech startup Virohan raises $7.5 Mn in ongoing Series B Healthcare edtech startup Virohan has raised Rs 65 crore ($7.5 million) as part of its ongoing Series B funding round, led by Mynavi Corporation. The round also saw participation from Virohan’s existing investors including Blume Ventures, Bharat Inclusive Technologies Seed Fund, and Rebright Partners. The funding will accelerate Virohan’s path to profitability through product innovation, operational efficiencies, and strategic talent expansion, the company said in a press release. Virohan works with universities such as UPES, BBD University, CMR University, Assam Don Bosco University, and G.H. Raisoni University to offer undergraduate programs in allied healthcare, nursing, and healthcare management, and partners with healthcare companies including Lenskart, Medanta, Healthians, and Dr. Lal PathLabs to support student placements. The seven-year-old firm claims to have partnered with more than 20 higher education institutions, trained over 13,000 healthcare students, and worked with over 2,000 healthcare employers to support graduate employability. Virohan has raised over $25 million in funding so far. According to TheKredible, after the latest share allotment, Mynavi Corporation will hold a 3.83% stake in the company, while Blume Ventures will continue as the largest shareholder with a 16.16% holding. The company is yet to file its FY25 financials. In FY24, Virohan reported operating revenue of Rs 21 crore, up from Rs 10.65 crore in FY23, while its losses widened 18% year on year to Rs 22 crore.

Download the medial app to read full posts, comements and news.